Clinical Implications of Tumor Necrosis Factor-Alpha, Interleukin-6 and Resistin in Coronary Artery Disease

DOI: 10.4236/wjcd.2014.49052   PDF   HTML     3,113 Downloads   4,061 Views   Citations


Tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) are involved in the progression of coronary artery disease (CAD). The cytokines’ levels are associated with the severity of CAD. We have recently reported on the association of resistin, a relatively novel cytokine with the pathogenesis of cardiovascular disease (CVD). Although the inflammatory cytokines’ impact on atherosclerosis is widely accepted, yet some controversy exists regarding the involvement of these factors in atherogenesis. The current review highlights the potential association of TNF-alpha, IL-6 and resistin SNPs (single nucleotide polymorphisms) with CAD. Molecular genetics data along with the intracellular signaling cascade mechanisms may have important clinical implications in the treatment of CAD.

Share and Cite:

Javed, Q. (2014) Clinical Implications of Tumor Necrosis Factor-Alpha, Interleukin-6 and Resistin in Coronary Artery Disease. World Journal of Cardiovascular Diseases, 4, 416-421. doi: 10.4236/wjcd.2014.49052.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Tracy, R.P. (2003) Thrombin, Inflammation and Cardiovascular Disease. Chest, 124, 49S-57S.
[2] Braunwald, E. (2008) Review Article: Biomarkers in Heart Failure. New England Journal of Medicine, 358, 2148-2159.
[3] Egashira, K. (2003) Molecular Mechanisms Mediating Inflammation in Vascular Disease: Special Reference to Monocyte Chemoattractant Protein-1. Hypertension, 41, 834-841.
[4] Hansson, G.K. (2005) Review Article: Inflmmation, Atherosseclerosis and Coronary Artery Disease. New England Journal of Medicine, 352, 1685-1695.
[5] Padovani, J.C., Pazin-Filho, A., Simoes, M.V., Marin-Neto, J.A., Zago, M.A. and Franco, R.F. (2000) Gene Polymorphisms in the TNF Locus and the Risk of Myocardial Infarction. Thrombosis Research, 100, 263-269.
[6] Pearson, T.A., George, A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O., et al. (2003) Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice; A Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107, 499-511.
[7] Calabrese, F., Elisa, C., Cristina, C., et al. (2004) Over Expression of Tumor Necrosis Factor (TNF-a) and TNF-a Receptor-1 in Human Viral Myocarditis: Clinicopathologic Correlations. Mordern Pathology, 17, 1108-1118.
[8] Levine, B., Kalman, J., Mayer, L., et al. (1990) Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure. New England Journal of Medicine, 323, 236-241.
[9] Elahi, M.M. and Matata, B.M. (2005) Genetic Diversity of Tumour Necrosis Factor: Implications on Cardiovascular Complications of Polymorphisms at Position –308 in the Promoter Region. The Cardiology, 1, 179-188.
[10] Brinkman, B.M. (1996) Relevance of the Tumor Necrosis Factor Alpha (TNF Alpha) –308 Promoter Polymorphism in TNF Alpha Gene Regulation. Journal of Inflammation, 46, 32-41.
[11] Patel, R., Lim, D.S., Reddy, D., Nagueh, S.F., Lutucuta, S., Sole, M.J., et al. (2000) Variants of Trophic Factors and Expression of Cardiac Hypertrophy in Patients with Hypertrophic Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 32, 2369-2377.
[12] Mellick, G.D. (2007) TNF Gene Polymorphism and Quantitative Trait Related to Cardiovascular Diseases: Getting to the Heart of the Matter. European Journal of Human Genetics, 15, 609-611.
[13] Deswal, A., Petersen, N.J., Feldman, A.M., Young, J.B., White, B.G. and Mann, D.L. (2001) Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST). Circulation, 103, 2055-2059.
[14] Torre-Amione, G., Kapadia, S., Benedict, C., Oral, H., Young, J.B. and Manna, D.L. (1996) Proinflammatory Cytokine Levels in Patients with Depressed Left Ventricular Ejection Fraction: A Report from the Studies of Left Ventricular Dysfunction (SOLVD). Journal of American College of Cardiology, 27, 1201-1206.
[15] Kubota, T., McNamara, D.M., Wang, J.J., Trost, M., McTiernan, C.F., Mann, D.L., et al. (1998) Effects of Tumor Necrosis Factor Gene Polymorphisms on Patients with Congestive Heart Failure. Circulation, 97, 2499-2501.
[16] Bidwell, J., Keen, L., Gallagher, G., Kimberly, R., Huizinga, T., McDermott, M.F., et al. (1999) Cytokine Gene Polymorphism in Human Disease: On-Line Databases. Immunology, 1, 3-19.
[17] Castell, J.V., Gómez-Lechón, M.J., David, M., Andus, T., Geiger, T., Trullenque, R., et al. (1989) Interleukin-6 Is the Major Regulator of Acute Phase Protein Synthesis in Adult Human Hepatocytes. FEBS Letters, 242, 237-239.
[18] Harris, T.B., Ferrucci, L., Tracy, R.P., Corti, M.C., Wacholder, S., Ettinger, W.H., et al. (1999) Associations of Elevated Interleukin-6 and C-Reactive Protein in Levels with Mortality in the Elderly. American Journal of Medicine, 106, 506-512.
[19] Biasucci, L.M., Liuzzo, G., Grillo, R.L., Caligiuri, G., Rebuzzi, A.G., Buffon, A., et al. (1999) Elevated Levels of C-Reactive Protein at Discharge in Patients with Unstable Angina Predict Recurrent Instability. Circulation, 99, 855-860.
[20] Biasucci, L.M., Liuzzo, G., Fantuzzi, G., Caligiuri, G., Rebuzzi, A.G., Ginnetti, F., et al. (1999) Increasing Levels of Interleukin (1L)-1Ra and IL-6 during the First Two Days of Hospitalization in Unstable Angina Are Associated with Increased Risk of IN-Hospital Coronary Events. Circulation, 99, 2079-2084.
[21] Tappia, P.S., Man, W.J. and Grimble, R.F. (1995) Influence of Unsaturated Fatty Acids on the Production of Tumour Necrosis Factor and Interleukin-6 by Rat Peritoneal Macrophages. Molecular and Cell Biochemistry, 143, 89-98.
[22] Maes, M., Song, C., Lin, A., De Jongh, R., Van Gastel, A., Kenis, G., et al. (1998) The Effects of Psychological Stress on Humans: Increased Production of Pro-Inflammatory Cytokines and Th1-Like Response in Stress-Induced Anxiety. Cytokine, 10, 313-318.
[23] Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V., Yudkin, J.S., Humphries, S., et al. (1998) The Effect of Novel Polymorphisms in the Interleukin-6 (IL-6) Gene on IL-6 Transcription and Plasma IL-6 Levels, and an Association with Systemic-Onset Juvenile Chronic Arthritis. Journal of Clinical Investigation, 102, 1369-1376.
[24] Losito, A., Kalidas, K., Santoni, S. and Jeffery, S. (2003) Association of Interleukin-6 ﹣174G/C Promoter Polymorphism with Hypertension and Left Ventricular Hypertrophy in Dialysis Patients. Kidney International, 64, 616-622.
[25] Humphries, S.E., Luong, L.A., Ogg, M.S., Hawe, E. and Miller, G.J. (2001) The Interleukin-6 174 G/C Polymorphism Is Associated with Risk of Coronary Heart Disease and Systolic Blood Pressure in Healthy Men. European Heart Journal, 22, 2243-2252.
[26] Brull, D.J., Montgomery, H.E., Sanders, J., Dhamrait, S., Luong, L., Rumley, A., et al. (2001) Interleukin-6 Gene ﹣174G > C and ﹣572G > C Promoter Polymorphisms Are Strong Predictors of Plasma Interleukin-6 Levels after Coronary Artery Bypass Surgery. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 1458-1463.
[27] Hussain, M., Asghar, M. and Javed, Q. (2010) Resistin Gene Promoter Region Polymorphism and the Risk of Hypertrophic Cardiomyopathy in Patients. Translational Research, 155, 142-147.
[28] Hussain, M., Bibi, S. and Javed, Q. (2011) Heritability of Genetic Variants of Resistin Gene in Patients with Coronary Artery Disease: A Family-Based Study. Clinical Biochemistry, 44, 618-622.
[29] Sheth, T., Nair, C., Nargundkar, M., Anand, S. and Yusuf, S. (1999) Cardiovascular and Cancer Mortality Canadians of European, South Asian, and Chinese Origin from 1979 to 1993: An Analysis of 1.2 Million Deaths. Canadian Medical Association Journal, 161, 132-138.
[30] McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D.R., et al. (2007) A Common Allele on Chromosome 9 Associated with Coronary Heart Disease. Science, 316, 1488-1491.
[31] Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., et al. (2007) A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction. Science, 316, 1491-1493.
[32] Preuss, M., Konig, I.R., Thompson, J.R., Erdmann, J., Absher, D., Assimes, T.L., et al. (2010) Design of the Coronary Artery Disease Genome-Wide Replication and Meta-Analysis (CARDIoGRAM) Study: A Genome-Wide Association Meta-Analysis Involving More than 22 000 Cases and 60 000 Controls. Circulation: Cardiovascular Genetics, 3, 1369-1376.
[33] Zhuang, J., Peng, W., Li, H., Wang, W., Wei, Y., Li, W. and Xu, Y. (2012) Methylation of p15INK4b and Expression of ANRIL on Chromosome 9p21 Are Associated with Coronary Artery Disease. PLoS ONE, 7, e47193.
[34] Javed, Q. and Murtaza, I. (2013) Therapeutic Potential of Tumor Necrosis Factor-Alpha Antagonists in Patients with Chronic Heart Failure. Heart, Lung and Circulation, 22, 323-327.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.